M
Michela Roberto
Researcher at Sapienza University of Rome
Publications - 82
Citations - 901
Michela Roberto is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 13, co-authored 64 publications receiving 525 citations.
Papers
More filters
Journal ArticleDOI
The sexist behaviour of immune checkpoint inhibitors in cancer therapy
Andrea Botticelli,Concetta Elisa Onesti,Ilaria Grazia Zizzari,Bruna Cerbelli,Paolo Sciattella,Mario Occhipinti,Michela Roberto,Francesca Di Pietro,Adriana Bonifacino,Michele Ghidini,Patrizia Vici,Laura Pizzuti,Chiara Napoletano,Lidia Strigari,Giulia d'Amati,Federica Mazzuca,Marianna Nuti,Paolo Marchetti +17 more
TL;DR: Different mechanisms could be involved in sex differences with regard to immunotherapy and these differences could be relevant to identify immunological targets in order to draw studies exploring novel combinations of immunotherapy agents.
Journal ArticleDOI
Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
Alessandro Rossi,Michela Roberto,Martina Panebianco,Andrea Botticelli,Federica Mazzuca,Paolo Marchetti +5 more
TL;DR: In this article, the main studies about clinical effects of several target inhibitors are reviewed, describing properly the most prominent mechanisms of both intrinsic and acquired resistance.
Journal ArticleDOI
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab.
Andrea Botticelli,Massimiliano Salati,Francesca Di Pietro,Lidia Strigari,Bruna Cerbelli,Ilaria Grazia Zizzari,Raffaele Giusti,Marco Mazzotta,Federica Mazzuca,Michela Roberto,Patrizia Vici,Laura Pizzuti,Marianna Nuti,Paolo Marchetti +13 more
TL;DR: A nomogram based on easily available and inexpensive clinical factors showing a good performance in predicting individual OS probability among NSCLC patients treated with nivolumab is developed and could be valuable to clinicians in more accurately driving treatment decision in daily practice as well as enrollment onto clinical trials.
Journal ArticleDOI
Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines
Federica Mazzuca,Concetta Elisa Onesti,Concetta Elisa Onesti,Michela Roberto,Marco Di Girolamo,Andrea Botticelli,Paola Begini,Lidia Strigari,Paolo Marchetti,Maurizio Muscaritoli +9 more
TL;DR: Lean body mass loss is associated with higher grade of toxicity in early breast cancer patients receiving adjuvant chemotherapy and L3 skeletal muscle index is an independent predictor of severe toxicity in multivariate analysis.
Journal ArticleDOI
Circulating tumor cells count predicts survival in colorectal cancer patients.
Adriana Romiti,Salvatore Raffa,Roberta Di Rocco,Michela Roberto,Annalisa Milano,Angelo Zullo,Laura Leone,Danilo Ranieri,Francesca Mazzetta,Emanuela Medda,Ida Sarcina,Viola Barucca,Chiara D'Antonio,Valeria Durante,Mario Ferri,Maria Rosaria Torrisi,Paolo Marchetti +16 more
TL;DR: It is found that the presence of CTCs is associated with a reduced survival in colorectal cancer patients and further studies aimed at testing such a predictive value in early stage coloreCTal cancer are awaited.